Publication:


abstract

Down syndrome is the most studied chromosomal abnormality, and the risk of having a child with Down syndrome increases as maternal age increases. The prevalence of Down syndrome has been increasing in the last decade because more women older than 35 years of age are having children. In recent decades, the rate of identification of fetal anomalies in the uterus has substantially increased. Diagnostically speaking, serious concerns yet remain within the obstetrical community regarding who should be recommended for invasive procedures. The FASTER, SURUSS, and BUN studies have attempted to address this issue. In the United States, the quadruple screen for Down syndrome (hcG, AFP, estriol, and inhibin-A) is the most commonly used test today. During the first trimester, the nuchal translucency measurement combined with serum markers hcG and PAPP-A (pregnancy-associated plasma protein-A) results in high detection rates and low false-positive rates. For Down syndrome screening, new methods of evaluation have been proposed; among these are integrated, sequential, and contingent modalities. Different trials have demonstrated that first-trimester screening for Down syndrome is very effective, but all conclude that combining screening during both trimesters allows for lower false-positive values and higher detection rates. In Puerto Rico, in spite of the fact that a large proportion of the population undergoes serum screening, the rate of Down syndrome live births remains steady. One important aspect that appears to limit prenatal diagnosis of Down syndrome in our population is a poor acceptance rate of diagnostic testing techniques such as amniocentesis. Also, a limited efficiency in the implementation of these screening methods as well as their diagnostic success has been observed for our patient population.

Related Articles
Prenatal screening for fetal aneuploidy in singleton pregnancies.
J Obstet Gynaecol Can. 2011
Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D, Langlois S, Wilson RD, Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada, Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists. J Obstet Gynaecol Can. 2011 Jul; 33(7):736-50.
Review Obstetrical complications associated with abnormal maternal serum markers analytes.
J Obstet Gynaecol Can. 2008
Review Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, Johnson JA, Langlois S, Summers A, et al. J Obstet Gynaecol Can. 2008 Oct; 30(10):918-49.
SURUSS in perspective.
Semin Perinatol. 2005
SURUSS in perspective.
Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. Semin Perinatol. 2005 Aug; 29(4):225-35.
First- and second-trimester evaluation of risk for Down syndrome.
Obstet Gynecol. 2007
First- and second-trimester evaluation of risk for Down syndrome.
Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, et al. Obstet Gynecol. 2007 Jul; 110(1):10-7.
Review [Down syndrome screening in France: the worst consensus].
J Gynecol Obstet Biol Reprod (...
Review [Down syndrome screening in France: the worst consensus].
Rozenberg P, Bussières L, Senat MV. J Gynecol Obstet Biol Reprod (Paris). 2007 Apr; 36(2):95-103. Epub 2007 Feb 6.